

Press Releases

All Years

[Advanced Search](#)

MAY 16, 2016

[Correcting and Replacing GAAP Net Loss on Consolidated Statement of Operations for First Quarter 2016](#)

- No changes to adjusted results or adjusted guidance from original earnings release issued on May 12, 2016

MAY 11, 2016

[Perrigo Company plc To Release First Quarter Calendar Year 2016 Results On May 12, 2016](#)

MAY 3, 2016

[Perrigo And Allergan Announce First-To-Market Launch Of Store Brand OTC Equivalent To Mucinex® 1200mg DM Extended-Release Tablets](#)

MAY 2, 2016

[Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin® Pump Topical Gel](#)

APR 28, 2016

[Perrigo Expands the Responsibilities of Sharon Kochan, Perrigo's Executive Vice President and General Manager, International, to Lead the Branded Consumer Healthcare Segment](#)

[Announces Reassignment of Mary Conroy as Executive Vice President and General Manager, Branded](#)

Announces Resignation of Marc Coucke as Executive Vice President and General Manager Branded Consumer Healthcare

APR 26, 2016

[Perrigo Company plc Announces Quarterly Dividend](#)

APR 25, 2016

[Perrigo Appoints John T. Hendrickson as Chief Executive Officer, Provides Preliminary First Quarter 2016 Selected Financial Results, and Updates Full Year 2016 Guidance](#)

Names Laurie Brlas as Chairman of the Board of Directors

APR 22, 2016

[Perrigo Responds To Market Rumors](#)

APR 12, 2016

[Perrigo Announces First-to-Market Launch of the OTC Store Brand Equivalent to Glucerna® Aseptic Adult Nutritional Shake](#)

MAR 23, 2016

[Perrigo And Allergan Announce First-To-Market Launch Of Store Brand OTC Equivalent To Mucinex® 1200mg ER Tablets](#)

MAR 16, 2016

[Perrigo Animal Health Unveils SENTRY® Vantaguard™ 2, SENTRY® Flea & Tick Collar for Dogs at Global Pet Expo](#)

MAR 16, 2016

[Perrigo Animal Health Unveils PetArmor® Advanced 2 Flea Treatment, PetArmor® Flea & Tick Collar for Dogs at GPE](#)

MAR 10, 2016

[Perrigo Company plc Announces The Closing Of A Senior Notes Offering By Its Finance Subsidiary, Perrigo Finance Unlimited Company](#)

MAR 10, 2016

[Perrigo Company To Present At The Barclays Global Healthcare Conference](#)

MAR 8, 2016

[Perrigo Company plc Announces the Pricing of a Senior Notes Offering by its Finance Subsidiary, Perrigo Finance Unlimited Company](#)

MAR 7, 2016

[Perrigo Company plc Announces Proposed Public Offering Of Senior Notes Of Its Finance Subsidiary, Perrigo Finance Unlimited Company](#)

MAR 1, 2016

[Perrigo Company To Present At Upcoming Investor Conferences](#)

FEB 23, 2016

[Perrigo Company To Present At The RBC Capital Markets Global Healthcare Conference](#)

FEB 19, 2016

[Perrigo Furthers Commitment to Ireland](#)

DUBLIN HEADQUARTERS CENTRAL TO EUROPEAN & GLOBAL GROWTH STRATEGY

FEB 18, 2016

[**Perrigo Company plc Reports Record Fourth Quarter & Calendar Year Net Sales And Adjusted Net Income**](#)

- Delivered record calendar year 2015 net sales of \$5.35 billion, an increase of 28% compared to the prior year; with adjusted net income of \$1.09 billion, an increase of 29% compared to the prior year; and adjusted earnings per share of \$7.59, an increase of 21% compared to the prior year

FEB 16, 2016

[**Perrigo Company plc Announces Quarterly Dividend**](#)

FEB 11, 2016

[**Perrigo Company plc To Announce Calendar Year & Fourth Quarter 2015 Earnings Results On February 18, 2016**](#)

JAN 25, 2016

[**Perrigo Completes The Acquisition Of Generic Retin-A® Portfolio, Further Enhancing Rx "Extended Topicals" Strategy**](#)

- Acquires high barrier-to-entry assets that fit well within Perrigo's unique Rx extended topicals portfolio

JAN 11, 2016

[**Perrigo Initiates Voluntary Product Recall In The U.S. Of Children's Guaifenesin Grape Liquid And Guaifenesin DM Cherry Liquid Due To A Potential Defect With The Dosage Cup**](#)

JAN 11, 2016

[**Perrigo Company plc Increases 2016 Full-Year Adjusted Earnings Per Share Guidance**](#)

- Expects full-year 2016 adjusted earnings per diluted share to be in a range of \$9.50 to \$10.10, an increase of 24% to 29% over 2015 adjusted earnings per diluted share guidance range of \$7.65 to \$7.85

Show 25  per page



<https://investor.perrigo.com/press-releases?l=25&o=350>